EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel Molecular Targets in the Treatment of Cardiac Hypertrophy

Mark Luedde, Hugo A Katus, Norbert Frey

Recent Patents on Cardiovascular Drug Discovery · 2006

DOI: 10.2174/157489006775244290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Cardiovascular Drug Discovery, 2006. Verfasst von Mark Luedde und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany. Die Arbeit wurde bisher 21-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Left ventricular hypertrophy represents the heart's response to increased biomechanical stress such as arterial hypertension or valvular heart disease. Cardiac hypertrophy has traditionally been considered a compensatory mechanism required to normalize wall tension and to maintain cardiac output. However, recent clinical studies as well as several animal models have shown that sustained cardiac hypertrophy is rather a maladaptive process, ultimately leading to heart failure and sudden death independent of the underlying cause of hypertrophy. Throughout the past decade, much effort has thus been spent on deciphering the molecular signaling pathways mediating cardiac growth. Identification of novel molecules regulating cardiac hypertrophy could offer the basis for a new generation of cardiovascular drugs. In this review we focus on recent insights into hypertrophic signaling and consider current and emerging approaches to inhibit hypertrophy with the ultimate goal to prevent or delay the onset of heart failure and sudden death in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsCalcineurinCardiomegalyCyclic GMPCyclic GMP-Dependent Protein KinasesDNA-Binding ProteinsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHistone DeacetylasesHumansIntracellular Signaling Peptides and ProteinsMAP Kinase Signaling SystemMuscle ProteinsNFATC Transcription FactorsPhosphatidylinositol 3-KinasesSTAT3 Transcription FactorSignal Transduction

Substanzen

CalcineurinCyclic GMPCyclic GMP-Dependent Protein KinasesDNA-Binding ProteinsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHistone DeacetylasesIntracellular Signaling Peptides and ProteinsMuscle ProteinsNFATC Transcription Factors

Autor:innen und Institutionen

  • Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.

Zitieren

APA

Luedde, M., Katus, H. A., & Frey, N. (2006). Novel Molecular Targets in the Treatment of Cardiac Hypertrophy. Recent Patents on Cardiovascular Drug Discovery. https://doi.org/10.2174/157489006775244290

Vancouver

Luedde M, Katus HA, Frey N. Novel Molecular Targets in the Treatment of Cardiac Hypertrophy. Recent Patents on Cardiovascular Drug Discovery. 2006. doi:10.2174/157489006775244290

BibTeX
@article{Luedde2006,
  author = {Luedde, Mark and Katus, Hugo A and Frey, Norbert},
  title = {Novel Molecular Targets in the Treatment of Cardiac Hypertrophy},
  journal = {Recent Patents on Cardiovascular Drug Discovery},
  year = {2006},
  doi = {10.2174/157489006775244290}
}
Kostenlos starten →